Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | RAPGEF4 | Q8WZA2 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5462283 | 0.83 | ALDH1A1 (0.50) | L3MBTL1CYP1A2LMNAALDH1A1RAPGEF4 | |
| SCHEMBL11140707 | 0.82 | ALDH1A1 (0.41) | LMNAALDH1A1GAAMAPTKMT2A | |
| SCHEMBL11881583 | 0.79 | RAPGEF4 (0.38) | LMNAALDH1A1GAARAPGEF4MAPT | |
| SCHEMBL11918917 | 0.79 | ALDH1A1 (0.56) | L3MBTL1CYP1A2ALDH1A1HTTMAPT | |
| SCHEMBL18550693 | 0.79 | GAA (0.47) | L3MBTL1CYP1A2LMNAALDH1A1GAA | |
| SCHEMBL5525050 | 0.79 | SIGMAR1 (0.50) | L3MBTL1LMNAALDH1A1GAAMAPT | |
| SCHEMBL144202 | 0.78 | KMT2A (0.50) | L3MBTL1CYP1A2ALDH1A1GAARAPGEF4 | |
| SCHEMBL11919007 | 0.76 | FFAR4 (0.41) | L3MBTL1CYP1A2ALDH1A1HTTMAPT | |
| SCHEMBL1192648 | 0.75 | GAA (0.67) | L3MBTL1ALDH1A1HTTGAAMAPT | |
| SCHEMBL6835277 | 0.75 | ALDH1A1 (0.51) | L3MBTL1LMNAALDH1A1HTTGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108369222-B | Opioid receptor modulators and uses thereof | 明尼苏达大学董事会 | 2021-06-04 | — | — | CN | disclosed |
| EP-3344997-B1 | OPIOID RECEPTOR MODULATORS AND USE THEREOF | UNIV MINNESOTA (US) | 2020-11-18 | — | — | EP | disclosed |
| EP-3344997-B1 | OPIOID RECEPTOR MODULATORS AND USE THEREOF | UNIV MINNESOTA (US) | 2020-11-18 | — | — | EP | disclosed |
| EP-3344997-A1 | OPIOID RECEPTOR MODULATORS AND USE THEREOF | Regents of the University of Minnesota (US) | 2018-07-11 | — | — | EP | disclosed |
| US-9827228-B2 | Opioid receptor modulators and use thereof | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2017-11-28 | — | — | US | disclosed |
| US-9827228-B2 | Opioid receptor modulators and use thereof | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2017-11-28 | — | — | US | disclosed |
| US-9827228-B2 | Opioid receptor modulators and use thereof | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2017-11-28 | — | — | US | disclosed |
| WO-2017039778-A1 | OPIOID RECEPTOR MODULATORS AND USE THEREOF | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2017-03-09 | — | — | WO | disclosed |
| WO-2017039778-A1 | OPIOID RECEPTOR MODULATORS AND USE THEREOF | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2017-03-09 | — | — | WO | disclosed |
| US-20170056377-A1 | OPIOID RECEPTOR MODULATORS AND USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-03-02 | — | — | US | disclosed |
| US-20170056377-A1 | OPIOID RECEPTOR MODULATORS AND USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-03-02 | — | — | US | disclosed |
| US-20170056377-A1 | OPIOID RECEPTOR MODULATORS AND USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170056377-A1 | OPIOID RECEPTOR MODULATORS AND USE THEREOF | OPRM1, OPRK1, OPRL1 | L3MBTL1 3880/4885CYP1A2 425/4885LMNA 4621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.